TITRE Suivi à long terme des patients exposés à un traitement par des lymphocytes T ayant un récepteur d’antigène chimérique (CAR) dirigé contre les cellules CD19 à base de lentivirus.
PROTOCOLE ID CCTL019A2205B
CLINICAL TRIAL.gov ID NCT02445222
TYPE(S) DE CANCER Pédiatrique divers
PHASE
TYPE D'ÉTUDE
INSTITUTION CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
3175 Chemin de la Côte Sainte-Catherine
(514) 345-4931
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Henrique Bittencourt
COORDONATEUR(RICE) Maud Frizot
maud.frizot@recherche-ste-justine.qc.ca
514-345-4931 poste 5467
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • All patients who have received anti-CD19 directed CART therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CD19-directed CART cells or from any CD19 CART trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology.
  • Patients who have provided informed consent for the long term follow up study prior to their study participation .
CRITÈRES D'EXCLUSION (EN)
  • There are no specific exclusion criteria for this study.